Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-obesity), By Surgery, And Segment Forecasts, 2014 - 2025

  • ID: 4429719
  • Report
  • 90 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • MORE
The global polycystic ovarian syndrome treatment market is expected to reach USD 5.1 billion by 2025, according to a new report. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery.

Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

Further Key Findings from the Study Suggest:
  • Constantly rising prevalence of PCOS is primarily driving the growth of this market across the globe
  • Initiatives undertaken by government bodies and market players to create awareness about benefits of early diagnosis and commercially available treatment for PCOS among women is boosting the market
  • Treatment of PCOS mainly includes lifestyle modification through balanced diet, exercise, and drugs such as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity agents, and antidepressants
  • Surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are preferred when patients do not respond to drug therapy
  • Insulin-sensitizing agents segment is dominating the market since these drugs are widely used for treatment of insulin resistance to prevent diabetes, which is a risk associated with PCOS
  • Oral Contraceptive Pills (OCPs) segment is expected to grow at the fastest rate followed by antiandrogen agents that are used for treating symptomatic conditions such as hirsutism and acne
  • North America is dominating the market followed by Europe. High awareness and availability of advanced healthcare facilities are factors responsible for the dominant share held by this region
  • Asia Pacific is expected to be the fastest growing region over the forecast period.Increasing government initiatives for raising awareness about symptoms & diagnosis of PCOS and available treatment are increasing the number of women being diagnosed with this syndrome in the region
  • China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players owing to presence of a large pool of obese female population, which is at high risk of PCOS
  • Key players in the market include AstraZeneca, Bayer AG, Merck KGaA, Abbott, Sanofi, Pfizer, Inc., Bristol-Myer Squibb Company, and Novartis AG. The market also includes other emerging players such as Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals, Inc., which are expected to grow significantly in the near future.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • MORE
Chapter 1 Research Methodology
1.1 Information procurement
1.2 Data Analysis
1.3 List of Data Sources

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Polycystic Ovarian Syndrome (PCOS) Treatment Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.1.1 Market Driver Analysis
3.1.1.1 Rising prevalence of PCOS
3.1.1.2 Growing genetic disorders
3.1.1.3 Rising awareness within the patients
3.1.2 Market Restraint Analysis
3.1.2.1 Side effects of the treatment therapy
3.2 Penetration & growth prospect mapping
3.3 Polycystic Ovarian Syndrome (PCOS) Treatment Market - PESTLE Analysis
3.4 Industry Analysis - Porter’s
3.5 Pipeline Analysis of Polycystic Ovarian Syndrome Treatment

Chapter 4 Polycystic Ovarian Syndrome (PCOS) Treatment Market: Drugs Estimates & Trend Analysis
4.1 Polycystic Ovarian Syndrome (PCOS) Treatment market: Drug class movement analysis
4.2 Drugs
4.2.1 Drugs market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.3 Oral Contraceptives
4.3.1 Oral contraceptive market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.3.2 Clomid
4.3.2.1 Clomid market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.3.3 Provera
4.3.3.1 Provera market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.4 Insulin-sensitizing agents
4.4.1 Insulin-sensitizing agents market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.4.2 Glucophage
4.4.2.1 Glucophage market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.4.3 Others
4.4.3.1 Others market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.5 Antiandrogen
4.5.1 Antiandrogen market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.5.2 Diane 35
4.5.2.1 Diane 35 market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.5.3 Aldactone
4.5.3.1 Aldactone market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.5.4 Anti-obesity agents
4.5.4.1 Anti-obesity agents market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.5.5 Xenical
4.5.5.1 Orlistat market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.5.6 Meridia
4.5.6.1 Sibutarmine market estimates & segment forecast, 2014 - 2025 (USD Billion)
4.5.7 Antidepressants
4.5.7.1 Antidepressants market estimates & segment forecast, 2014 - 2025 (USD Billion)

Chapter 5 Polycystic Ovarian Syndrome (PCOS) Treatment Market: Surgery Estimates & Trend Analysis
5.1 Polycystic Ovarian Syndrome (PCOS) treatment market: Surgery movement analysis
5.2 Surgery
5.2.1 Surgeries market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.3 Ovarian wedge resection
5.3.1 Ovarian wedge resection market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.4 Laparoscopic ovarian drilling
5.4.1 Laparoscopic ovarian drilling market estimates & segment forecast, 2014 - 2025 (USD Billion)

Chapter 6 Polycystic Ovarian Syndrome (PCOS) Treatment Market: Regional Estimates & Trend Analysis, by Drugs and Surgery
6.1 Polycystic Ovarian Syndrome(PCOS) treatment market share by region, 2016 & 2024
6.2 North America
6.2.1 North America polycystic ovarian syndrome market, 2014 - 2025 (USD Billion)
6.2.2 U.S.
6.2.2.1 U.S. polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.2.2.2 U.S. polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
6.2.3 Canada
6.2.3.1 Canada polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.2.3.2 Canada polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
6.3 Europe
6.3.1 Europe polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
6.3.2 UK
6.3.2.1 UK polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.3.2.2 UK polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
6.3.3 Germany
6.3.3.1 Germany polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.3.3.2 Germany polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
6.4 Asia Pacific
6.4.1 Asia Pacific polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
6.4.2 Japan
6.4.2.1 Japan polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
6.4.2.2 Japan polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
6.4.3 China
6.4.3.1 China polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.4.3.2 China polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion
6.5 Latin America
6.5.1 Latin America polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
6.5.2 Brazil
6.5.2.1 Brazil polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.5.2.2 Brazil polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
6.5.3 Mexico
6.5.3.1 Mexico polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.5.3.2 Mexico polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
6.6 MEA
6.6.1 MEA polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
6.6.2 South Africa
6.6.2.1 South Africa polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
6.6.2.2 South Africa polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)

Chapter 7 Competitive Landscape
7.1 List of players operating in the market
7.2 Company Profiles
7.2.1 AstraZeneca
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Bayer AG
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 Merck KGaA
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Abbott Laboratories
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 Pfizer Inc.
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 Sanofi SA
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 Bristol-Myers Squibb Company
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 Ferring Pharmaceuticals, Inc.
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Teva Pharmaceuticals Industries Limited
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives
7.2.10 Novartis AG
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Product benchmarking
7.2.10.4 Strategic initiatives

List of Tables

Table 1 North America polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 2 North America polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 3 North America polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 4 U.S. polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 5 U.S. polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 6 U.S. polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 7 Canada polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 8 Canada polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 9 Canada polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 10 Europe polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 11 Europe polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 12 Europe polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 13 U.K. polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 14 U.K. polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 15 U.K. polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 16 Germany polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 17 Germany polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 18 Germany polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 19 Asia Pacific polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 20 Asia Pacific polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 21 Asia Pacific polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 22 Japan polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 23 Japan polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 24 Japan polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 25 China polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 26 China polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 27 China polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 28 Latin America polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 29 Latin America polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 30 Latin America polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 31 Brazil polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 32 Brazil polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 33 Brazil polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 34 Mexico polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 35 Mexico polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 36 Mexico polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 37 MEA polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 38 MEA polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 39 MEA polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
Table 40 South Africa polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
Table 41 South Africa polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
Table 42 South Africa polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 Polycystic Ovarian Syndrome (PCOS) Treatment Market PESTLE Analysis
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Polycystic Ovarian Syndrome (PCOS) treatment market drug class outlook key takeaways
FIG. 16 Polycystic Ovarian Syndrome (PCOS) treatment market: Drug class movement analysis
FIG. 17 Drugs market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 18 Oral contraceptives market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 19 Clomid market estimates & segment forecast market, 2014 - 2025 (USD Billion)
FIG. 20 Provera market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 21 Insulin-sensitizing agents market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 22 Glucophage market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 23 Others market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 24 Antiandrogen market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 25 Diane 35 market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 26 Aldactone market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 27 Anti-obesity agents market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 28 Orlistat market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 29 Sibutarmine market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 30 Polycystic Ovarian Syndrome(PCOS) treatment market applications outlook key takeaways
FIG. 31 Polycystic Ovarian Syndrome (PCOS) treatment market: Surgery movement analysis
FIG. 32 Surgeries market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 33 Ovarian wedge resection market estimates & segment forecast, 2014 - 2025 (USD Billion)
FIG. 34 Laparoscopic ovarian drilling market estimates & segment forecast market, 2014 - 2025 (USD Billion)
FIG. 35 Regional market place: Key takeaways
FIG. 36 Regional outlook, 2015 & 2024
FIG. 37 North America polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 38 U.S. polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 39 Canada polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 40 Europe polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 41 UK polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 42 Germany polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 43 Asia Pacific polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 44 Japan polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 45 China polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 46 Latin America polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 47 Brazil polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 48 Mexico polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 49 MEA polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 50 South Africa polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
FIG. 51 Strategy framework
FIG. 52 Participant categorization
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca
  • Bayer AG
  • Merck KGaA
  • Abbott Laboratories
  • Pfizer Inc.
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • Ferring Pharmaceuticals, Inc.
  • Teva Pharmaceuticals Industries Limited
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll